<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00679250</url>
  </required_header>
  <id_info>
    <org_study_id>GRAY09</org_study_id>
    <secondary_id>2004-000683-27</secondary_id>
    <nct_id>NCT00679250</nct_id>
  </id_info>
  <brief_title>To Evaluate Adenosine Monophosphate and Allergen Challenge in Allergic Rhinitis</brief_title>
  <official_title>A Placebo Controlled Trial to Evaluate The Effects of Levocetirizine on Nasal Allergen Challenge And Adenosine Monophosphate Challenge In Patients With Intermittent and Persistent Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brian J Lipworth</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Dundee</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allergic rhinitis is a common condition characterize by inflammation of the upper airways.
      Third generation antihistamines have been demonstrated effective in the treatment of this
      condition. Allergen challenge can be use to assess the effects of drugs in allergic rhinitis,
      adenosine monophosphate may also be used as a means to investigate these effects but as yet
      its effects have yet to be compared to allergen challenge. We intend to compare the effects
      of levocetirizine at a single dose of 5mg on allergen and AMP challenge compared to placebo
      in a double blind cross-over study. The study will include 20 patients with allergic
      rhinitis. Each patient will have allergen and AMP challenge on placebo and active treatment.
      The primary outcome variable will be the change in concentration of AMP/Allergen required to
      produce a 20% drop in nasal flow as manifest by peak nasal inspiratory flow. A 1 doubling
      dose change in concentration of challenge medium to cause a 20% drop in nasal flow will be
      deemed significant. We will also measure time to recovery after both challenges. AMP
      challenge is a safe alternative to allergen challenge and does not have the risk of
      anaphylaxis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Provocative concentration of AMP or Allergen required to cause a 20% drop in Peak Nasal Inspiratory Flow.</measure>
    <time_frame>1 hour</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recovery Time Profile after nasal AMP and Allergen challenge</measure>
    <time_frame>1 hour</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Levocetirizine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo to levocetirizine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levocetirizine</intervention_name>
    <description>5 mg once nightly before visit</description>
    <arm_group_label>Levocetirizine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo to levocetirizine</intervention_name>
    <description>1 tablet once nightly before visit</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female 16-75

          -  Patients with persistent rhinitis must be skin prick positive to house dust mite with
             perennial symptoms

          -  Patients with seasonal rhinitis should be skin prick positive to grass/tree pollen
             with seasonal symptoms

          -  Concomitant asthma is permitted in those with rhinitis if FEV1 &gt;60%

          -  No recent exacerbations of asthma or chest infections if asthmatic

          -  Able to perform all of the techniques necessary to carry out challenge testing

          -  Must be compliant to study medication

          -  Must give informed consent

        Exclusion Criteria:

          -  Male or female outwith the above age range

          -  Negative skin prick testing

          -  Patients with concomitant asthma with FEV1 less than 60% predicted

          -  Patients with asthma with recent chest infection or exacerbation

          -  Pregnant females, those at risk of becoming pregnant or breast feeding. Females must
             be on adequate contraception for the whole study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arun Nair, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Dundee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ninewells Hospital and Medical School (Tayside NHS Trust, University of Dundee)</name>
      <address>
        <city>Dundee</city>
        <state>Angus</state>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perth Royal Infirmary</name>
      <address>
        <city>Perth</city>
        <state>Perthshire</state>
        <zip>PH1 1NX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Togias A. Rhinitis and asthma: evidence for respiratory system integration. J Allergy Clin Immunol. 2003 Jun;111(6):1171-83; quiz 1184. Review.</citation>
    <PMID>12789212</PMID>
  </reference>
  <reference>
    <citation>Bousquet J, Van Cauwenberge P, Khaltaev N; Aria Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001 Nov;108(5 Suppl):S147-334. Review.</citation>
    <PMID>11707753</PMID>
  </reference>
  <reference>
    <citation>Clough GF, Boutsiouki P, Church MK. Comparison of the effects of levocetirizine and loratadine on histamine-induced wheal, flare, and itch in human skin. Allergy. 2001 Oct;56(10):985-8.</citation>
    <PMID>11576078</PMID>
  </reference>
  <reference>
    <citation>Wang DY, Hanotte F, De Vos C, Clement P. Effect of cetirizine, levocetirizine, and dextrocetirizine on histamine-induced nasal response in healthy adult volunteers. Allergy. 2001 Apr;56(4):339-43.</citation>
    <PMID>11284803</PMID>
  </reference>
  <reference>
    <citation>Lee DK, Gray RD, Wilson AM, Robb FM, Soutar PC, Lipworth BJ. Single and short-term dosing effects of levocetirizine on adenosine monophosphate bronchoprovocation in atopic asthma. Br J Clin Pharmacol. 2004 Jul;58(1):34-9.</citation>
    <PMID>15206990</PMID>
  </reference>
  <reference>
    <citation>Terada N, Hamano N, Kim WJ, Hirai K, Nakajima T, Yamada H, Kawasaki H, Yamashita T, Kishi H, Nomura T, Numata T, Yoshie O, Konno A. The kinetics of allergen-induced eotaxin level in nasal lavage fluid: its key role in eosinophil recruitment in nasal mucosa. Am J Respir Crit Care Med. 2001 Aug 15;164(4):575-9.</citation>
    <PMID>11520718</PMID>
  </reference>
  <reference>
    <citation>Wilson AM, Sims EJ, Orr LC, Robb F, Lipworth BJ. An evaluation of short-term corticosteroid response in perennial allergic rhinitis using histamine and adenosine monophosphate nasal challenge. Br J Clin Pharmacol. 2003 Apr;55(4):354-9.</citation>
    <PMID>12680883</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2008</study_first_submitted>
  <study_first_submitted_qc>May 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2008</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Dundee</investigator_affiliation>
    <investigator_full_name>Brian J Lipworth</investigator_full_name>
    <investigator_title>Professor (Clinical) Airway allergy and COPD</investigator_title>
  </responsible_party>
  <keyword>allergic rhinitis</keyword>
  <keyword>levocetirizine</keyword>
  <keyword>nasal provocation testing</keyword>
  <keyword>nasal allergen challenge</keyword>
  <keyword>nasal adenosine monophosphate challenge</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenosine</mesh_term>
    <mesh_term>Levocetirizine</mesh_term>
    <mesh_term>Cetirizine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

